These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://lillivdvn265966.aboutyoublog.com/48122819/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide